HIV/AIDs presents significant treatment challenges due to increasing resistance to current antiretroviral drugs. This resistance is exacerbated in low- and middle-income countries due to drug misuse, inadequate drug supply, and poor treatment monitoring. Despite these challenges, there has been progress in developing new ARV drugs targeting various components of HIV. This review, updated as of […]
According to preliminary data, individuals with HIV who are not able to achieve viral suppression with oral treatments may benefit from long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV). Utilizing the Consolidated Framework for Implementation Research, a research conducted at Ward 86 in San Francisco examined patient, provider, and contextual characteristics that impact the implementation of LA-CAB/RPV.
The United States legalized the use of long-acting injectable pre-exposure prophylaxis for HIV prevention (LAI-PrEP) in 2021. However, little is known about how transgender and nonbinary young adults, a population that faces significant obstacles to HIV prevention, see LAI-PrEP. The study looks at this population’s perceptions of long-acting injectable PrEP’s acceptability, convenience, and efficacy compared
For the prevention of HIV in cisgender women, there are variations in the uptake, adherence, and durability of preexposure prophylaxis. This study tested the effectiveness of subcutaneous lenacapavir and daily oral emtricitabine–tenofovir alafenamide (F/TAF) versus daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) in preventing HIV among adolescent girls and young women in South Africa and Uganda.
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women Read More »
Five long-acting (LA) antiretrovirals (ARVs)—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine—are now available in a few countries for HIV-1 prevention and treatment. To integrate LA ARVs into routine clinical practice, significant changes in HIV-1 care are needed. Consensus recommendations will guide doctors in the effective and safe use of these new, complex agents. These guidelines aim
The uptake of pre-exposure prophylaxis (PrEP) remains low among eligible individuals, with some preferring alternatives like long-acting injectable PrEP (LAI-PrEP) over daily oral PrEP. This study investigated the feasibility of offering LAI-PrEP through pharmacies in California, where pharmacists are authorized to provide oral PrEP independently. Using both statistical and qualitative analysis, the study identified factors
In the United States, HIV infections disproportionately afflict Latino men who have sex with men (LMSM). Pre-exposure prophylaxis, or PrEP, has not been widely adopted by LMSM as a means of preventing HIV. Injectable PrEP with a long half-life (LAI-PrEP) may help with behavioral, cognitive, and structural adherence difficulties. The purpose of our study was
Long-acting injectable therapies like rilpivirine and cabotegravir have notably influenced HIV treatment. Administered every few months, these injections offer an alternative to daily oral medications, which may benefit patients who have difficulty with adherence. The article discusses the potential benefits of these therapies, including improved adherence and convenience, while also addressing challenges such as cost,
Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment Read More »
Emtricitabine/tenofovir disoproxil fumarate (F/TDF) oral pre-exposure prophylaxis (PrEP) has a strong efficacy against HIV-1 acquisition. In different settings, 72 prospective studies of daily oral F/TDF PrEP were carried out to assess the incidence of HIV-1, medication resistance, adherence, and bone and renal safety.
Pre-exposure prophylaxis (PrEP) is one HIV preventive strategy that is widely used, yet AIDS cases still outnumber treatment and prevention attempts. Significant obstacles still exist, including stigma, prejudice, and lack of access, especially for vulnerable populations like women, minorities, and LGBTQ people. In order to address these problems through a comprehensive approach to sexual health
